Etiology and management of anemia in patients with heart failure: how much iron is missing?
Anemia is common among patients with heart failure (HF) and has been associated with worse prognosis. To date, it is not well known whether correction of anemia in these patients can improve outcome. Proposed modalities for correction of anemia have been either administration of erythropoiesis-stimulating proteins, which appears plausible in patients with concomitant renal failure (so-called cardiorenal syndrome), or iron supplementation, which is particularly attractive in patients with no overt renal failure and chronic disease anemia with some degree of iron deficiency. This article reviews the rationale for anemia correction and the latest randomized clinical trial assessing clinical utility of erythropoiesis-stimulating proteins and/or iron supplementation through oral or intravenous administration in anemic HF patients.
Beck da Silva
Luis
L
Heart Failure and Cardiac Transplantation Units, Divisions of Cardiology at the Hospital de Clínicas de Porto Alegre Federal University of Rio Grande do Sul, Medical School, Porto Alegre, Brazil. lbneto@hcpa.ufrgs.br
Rohde
Luis E
LE
Clausell
Nadine
N
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D004921:Erythropoietin / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D058085:Iron Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D015995:Prevalence; D012307:Risk Factors
D058085:Iron Compounds; D004921:Erythropoietin